Pharsight

1. Idose Tr patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10206813	GLAUKOS	Implants with controlled drug delivery features and methods of using same	Oct, 2030 (6 years from now)
US11426306	GLAUKOS	Implants with controlled drug delivery features and methods of using same	Oct, 2030 (6 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Dec 13, 2026

Market Authorisation Date: 13 December, 2023

Treatment: NA

Dosage: IMPLANT;INTRACAMERAL

Strength	Dosage	Availability
75MCG	IMPLANT;INTRACAMERAL	Prescription

Application	Filing Date	Opposition Party	Legal Status

EP15202422A	2018-02-12	actrevo GmbH	Granted and Under Opposition
EP15202422A	2018-02-09	ZAKLADY FARMACEUTYCZNE POLPHARMA S.A.	Granted and Under Opposition
EP15202422A	2018-02-09	Generics [UK] Limited (trading as Mylan)	Granted and Under Opposition
EP15202422A	2018-02-07	Bausch & Lomb Incorporated	Granted and Under Opposition
EP15202422A	2018-02-01	Instone, Terry/Appleyard Lees IP LLP/Read, Howard	Granted and Under Opposition
EP12193597A	2018-01-26	Alfred E. Tiefenbacher (GmbH & Co. KG)	Granted and Under Opposition
EP12193597A	2018-01-26	Generics [UK] Limited (trading as Mylan)	Granted and Under Opposition
EP09722278A	2016-02-29	Generics [UK] Limited (trading as Mylan)	Granted and Under Opposition
EP09722278A	2016-02-16	Alfred E. Tiefenbacher (GmbH & Co. KG)	Granted and Under Opposition
EP09722278A	2016-02-12	Pohlman, Sandra M.	Granted and Under Opposition

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9144561	NOVARTIS	Pharmaceutical compositions having desirable bioavailability	Mar, 2029 (4 years from now)
US8754123	NOVARTIS	Pharmaceutical compositions having desirable bioavailability	May, 2029 (5 years from now)
US8178582	NOVARTIS	Pharmaceutical compositions having desirable bioavailability	Oct, 2029 (5 years from now)
US8722735	NOVARTIS	Pharmaceutical compositions having desirable bioavailability	Oct, 2029 (5 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	May 15, 2017

Market Authorisation Date: 15 May, 2014

Treatment: NA

Dosage: SOLUTION/DROPS;OPHTHALMIC

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
0.00003	30 Dec, 2015	1		10 Oct, 2029	Extinguished

Strength	Dosage	Availability
0.003% Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	SOLUTION/DROPS;OPHTHALMIC	Discontinued

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5510383	ALCON PHARMS LTD	Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension	Aug, 2013 (10 years ago)
US5889052	ALCON PHARMS LTD	Use of cloprostenol and fluprostenol analogues to treat glaucoma and ocular hypertension	Dec, 2014 (9 years ago)
US6011062	ALCON PHARMS LTD	Storage-stable prostaglandin compositions	Dec, 2014 (9 years ago)
US5849792	ALCON PHARMS LTD	Storage-stable prostaglandin compositions	Dec, 2014 (9 years ago)
US5631287	ALCON PHARMS LTD	Storage-stable prostaglandin compositions	Dec, 2014 (9 years ago)

Market Authorisation Date: 16 March, 2001

Treatment: Method for treating glaucoma and ocular hypertension; Method of stabilizing prostaglandin

Dosage: SOLUTION/DROPS;OPHTHALMIC

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
0.00004	28 Nov, 2008	1		22 Dec, 2014	Extinguished

Strength	Dosage	Availability
0.004% Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	SOLUTION/DROPS;OPHTHALMIC	Discontinued

Application	Filing Date	Opposition Party	Legal Status

EP07842925A	2016-03-17	Pohlman, Sandra M.	Patent maintained as amended
EP07842914A	2012-08-02	Pohlman, Sandra M.	Patent maintained as amended
EP07842914A	2012-08-02	ALLERGAN, INC.	Patent maintained as amended

Patent	Proceeding Filing Date	Status	Respondent	Petitioner

US8268299	March, 2017	FWD Entered	Alcon Research, Ltd.	Argentum Pharmaceuticals LLC
US8268299	July, 2013	Terminated-Settled	ALCON RESEARCH, LTD.	Apotex Corp.
US8323630	July, 2013	Terminated-Settled	ALCON RESEARCH, LTD.	Apotex Corp.
US8388941	July, 2013	Terminated-Settled	Alcon Research, Ltd.	Apotex Corp.

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5510383	SANDOZ	Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension	Aug, 2013 (10 years ago)
US5889052	SANDOZ	Use of cloprostenol and fluprostenol analogues to treat glaucoma and ocular hypertension	Dec, 2014 (9 years ago)
US8388941	SANDOZ	Self preserved aqueous pharmaceutical compositions	Sep, 2027 (3 years from now)
US8323630	SANDOZ	Self-preserved aqueous pharmaceutical compositions	Sep, 2027 (3 years from now)
US8268299	SANDOZ	Self preserved aqueous pharmaceutical compositions	Oct, 2029 (5 years from now)

Market Authorisation Date: 21 September, 2006

Treatment: Method for treating glaucoma and ocular hypertension

Dosage: SOLUTION/DROPS;OPHTHALMIC